热门标签

新2网址(www.hg108.vip):Sanofi ends cancer drug trials

时间:1周前   阅读:1   评论:3

新2网址www.hg108.vip)实时更新发布最新最快的新2代理线路、新2会员线路、新2备用登录网址、新2手机版登录网址、新2皇冠登录网址。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

新2网址大全www.hg108.vip)实时更新发布最新最快最有效的新2网址和新2最新网址,包括新2手机网址,新2备用网址,皇冠最新网址,新2足球网址,新2网址大全。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:五湖四海足球吧:Grab falls US$13bil behind Indonesia’s GoTo

下一篇:皇冠信用网开户:By2方回应妹妹陪姐姐逛婚纱店被偶遇:由不得你催

网友评论